Homology Medicines, Inc.(FIXX)

Sector:

Healthcare

Description:

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Current Price

$0.98

RSI

38.73

Market Capitalization:

171M

Beta:

-0.587

Volume:

55,704

Analyst Target Price:

$ 14.67

Economiic Fair Price:


November 21, 2022
November 10, 2022
Q3
N/A
N/A
N/A
N/A
N/A
43.2M
29.8M
-1.732
-281.90 %
0.614
-0.524

-156.30 %
2205.47 %
-103.11 %
-52.18 %
-3.22 %
-239.23 %

$ 34M
1157.25 %
$ 2.7M
62.18 %
$ 1.7M
-54.78 %
$ 3.7M

$ -112.1M
-14.36 %
$ -98.1M
13.36 %
$ -113.2M
-67.69 %
$ -67.5M
-1593.10 %
$ 4.5M
143.17 %
$ -10.5M

$ -95.8M
25.59 %
$ -128.7M
-23.84 %
$ -103.9M
-81.62 %
$ -57.2M

News

Press Releases

Notable Dates